



# FIG. 1




ARC2081

FIG. 2




300








**FIG. 3A**

1C1 competes for Hp binding to Neat-1

**FIG. 3B**

2F4 competes for Hp with Neat-2









FIG. 5

FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D






FIG. 8



# FIG. 9A


Kidney Distribution



USA300 1.65e8


# FIG. 9B

Kidney Distribution




USA300 2.05e8

FIG. 10  
Inhibition of ClfA



|              |       |       |        |
|--------------|-------|-------|--------|
|              | 23D6  | 27H4  | 11H10  |
| IC50 (µg/ml) | 1.916 | 4.801 | 0.8713 |

FIG. 11



12/18

FIG. 12








FIG. 13



Challenge dose: 2.98e7 cfu

FIG. 14



Challenge dose: 2.89e7 cfu

Figure 15






Figure 16

LC10/11H10 Combo effect on IV lethal challenge  
with CA-MRSA USA300 (strain SF8300, 6.4e7 cfu/mouse)

B.




C.



p value (CFU): Mann Whitney U test  
p value (Survival): Log-rank (Mantel-Cox) test


**Figure 17**  
**LC10/11H10 Combo effect on IV lethal challenge**  
**with HA-MRSA USA100 (strain NRS382, 9.2e7 cfu/mouse)**



*p value: Log Rank (mantel-cox) test*

Figure 18

LC10/11H10 Combo effect on IV lethal challenge  
with HA-MSSA USA200 (strain NRS261,  $1.18 \times 10^8$  cfu/mouse)



p value: Log Rank (mantel-cox) test